

# CNX-2006

Catalog No: tcsc2782



## Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



## Specifications

### CAS No:

1375465-09-0

### Formula:

$C_{26}H_{27}F_4N_7O_2$

### Pathway:

JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

### Target:

EGFR;EGFR

### Purity / Grade:

>98%

### Solubility:

DMSO :  $\geq 52$  mg/mL (95.32 mM)

### Observed Molecular Weight:


545.53

## Product Description

CNX-2006 is a mutant-selective and irreversible **EGFR** inhibitor with an **IC<sub>50</sub>** below 20 nM for EGFR<sup>T790M</sup>.

IC50 & Target: IC50: 20 nM (EGFR<sup>T790M</sup>)[1]

***In Vitro:*** CNX-2006 inhibits EGFR-T790M cells growth up to 1000-fold more compared to wild-type EGFR cells. EGFR inhibition is observed in cells harbouring the T790M mutation at IC<sub>50</sub> values below 20 nM after 1 hour exposure to the drug. CNX-2006 also significantly reduces the volume of tumor spheres derived from H1975 cells<sup>[1]</sup>. CNX-2006 exhibits specificity and potent activity against T790M. The drug also shows activity against uncommon EGFR mutations including G719S, L861Q, an exon 19 insertion mutant (I744-K745insKIPVAL), and T854A, but not an exon 20 insertion (H773-V774HVdup). In an *in vitro* resistance model, CNX-2006 significantly inhibits the emergence of resistant cells. Chronic exposure to escalating doses of CNX-2006 fails to select for and/or enhance T790M-mediated resistance using PC-9 or HCC827 cells (both harboring exon 19 deletions), or PC-9/ER and HCC827/ER cells with existing T790M and resistance to erlotinib<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!